In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.70018 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Olivier Schueller und 4 weiteren Autor:innen. Beteiligte Einrichtung: Kadmon, a Sanofi Comp, any, Cambridge, MA, USA. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily G, Member 2, Glucuronosyltransferase, Liver-Specific Organic Anion Transporter 1, Neoplasm Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Belumosudil is an oral selective rho‐associated coiled‐coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft‐versus‐host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil. In vitro assessments suggested that belumosudil may inhibit uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), P‐glycoprotein (P‐gp), organic anion transporting polypeptide 1B1 (OATP1B1), and breast cancer resistance protein (BCRP), resulting in drug–drug interactions (DDIs). This three‐part clinical DDI study (NCT05806567) was conducted to assess the effect of multiple doses of belumosudil (200 mg daily) on the single‐dose pharmacokinetics of raltegravir (UGT1A1‐sensitive substrate), dabigatran etexilate (P‐gp‐sensitive substrate), and rosuvastatin calcium (OATP1B1/BCRP‐sensitive substrate). Although there was no marked change in raltegravir exposure after coadministration with belumosudil, exposure to the glucuronide metabolite was decreased by 39.6% (area under the curve from time 0 to the time of last measurable concentration [AUC 0‐last ]) and 42.4% (maximum observed concentration [C max ]), suggesting that belumosudil is an in vivo inhibitor of UGT1A1. There was an approximate 2‐fold increase in C max , AUC 0‐last , and AUC from time 0 extrapolated to infinity (AUC 0‐inf ) for dabigatran etexilate, suggesting a potential and clinically relevant DDI for belumosudil and sensitive P‐gp substrates. C max and AUC 0‐last for rosuvastatin calcium increased by 3.6‐fold and 4.6‐fold, respectively, suggesting a clinically relevant interaction with drugs that are substrates of OATP1B1 or BCRP. There was no impact of coadministration with raltegravir, dabigatran etexilate, or rosuvastatin calcium on belumosudil pharmacokinetics, and belumosudil was well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kadmon, a Sanofi Comp, any, Cambridge, MA, USA.
- Nuventra, Inc., Durham, NC, USA.
- Sanofi, Ghent, Belgium.
- Sanofi, Cambridge, MA, USA.
ORCID-Profile: Olivier Schueller, Felix Beck
Zitieren
APA
Schueller, O., Lohmer, L., Beck, F., Patel, J., & Sahi, J. (2025). In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70018
Vancouver
Schueller O, Lohmer L, Beck F, Patel J, Sahi J. In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70018
BibTeX
@article{Schueller2025,
author = {Schueller, Olivier and Lohmer, Lauren and Beck, Felix and Patel, Jeegar and Sahi, Jasminder},
title = {In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.70018}
}
EUVIMED